ALT Kaplan\u2013Meier analysis of the primary efficacy and safety endpoints. (A) The incidence of the primary efficacy endpoint, defined as a composite of all-cause death or thromboembolic events (myocardial infarction, definite stent thrombosis, stroke, or systemic embolism). (B) The primary safety endpoint, defined as bleeding (International Society on Thrombosis and Haemostasis major or clinically relevant non-major bleeding). Percentages are Kaplan\u2013Meier estimates at 12 months (day 360). Hazard ratios compare the 1-month dual therapy group with the 12-month dual therapy group and were estimated using Cox proportional-hazards models with follow-up censored at day 360. PCI=percutaneous coronary intervention. Copyright: 2026 Elsevier Ltd. All rights are reserved.